News from Zyme and the companies we work with.

April 24, 19

US Patent Office Grants Charpentier/Doudna Key CRISPR Patent

US patent number 10,266,850 was previously involved in an interference proceeding  DUBLIN, Ireland, 23 April 2019: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced today that … Continue reading →

April 24, 19

TC BioPharm initiates Phase I trial of allogeneic gamma delta T cell therapy in Acute Myeloid Leukemia patients

Study to provide safety data on allogeneic use of GDTs prior to subsequent use of CAR-modified variants Glasgow, UK, 24 April 2019: TC BioPharm (TCB), a developer of allogeneic CAR-T immuno-oncology products, and leaders in Gamma Delta T (GDT) cell … Continue reading →

April 23, 19

Start Codon founded in Cambridge, UK, to deliver premier life science and healthcare business acceleration program

Start Codon, located in the heart of the Cambridge Cluster, aims to provide a much-needed world-class life science accelerator that offers significant funding and support to rapidly translate the most disruptive and innovative research into successful start-up companies. Start Codon’s … Continue reading →

April 9, 19

Bio-Rad Introduces Isotype-Specific Secondary Antibodies

HERCULES, Calif.–April 09, 2019–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the … Continue reading →

April 8, 19

Metrion Biosciences appoints Dr Andrew Southan as Chief Executive Officer

Cambridge, UK, 08 April 2019:  Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief … Continue reading →

April 3, 19

European Patent Office Grants 3rd Charpentier/Doudna Patent Covering Uses of CRISPR/Cas9 in Human and Animals Cells

EPO Patent No. 3,401,400 issued to Dr. Emmanuelle Charpentier, University of California and University of Vienna  DUBLIN, Ireland, 03 April 2019: ERS Genomics Limited announced today that the European Patent Office (EPO) has issued a new patent to Dr. Emmanuelle Charpentier, … Continue reading →

April 3, 19

TTP plc spin-out Cellular Highways Ltd to commercialise next-generation cell-sorting technology

TTP plc invests £1.7m ($2.2m), to fast-track development of first commercial product, Highway 1™, bench-top cell-sorting instrument Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput … Continue reading →

April 1, 19

Mogrify subsidiary Chondrogenix secures funding from SBRI Healthcare to advance regenerative cartilage therapy to the clinic

Chondrogenix will use Mogrify’s data-driven conversion platform to generate a safe, efficient and scalable source of cartilage cells for the treatment of osteoarthritis Cambridge, UK, 1st April 2019: Chondrogenix, a wholly owned subsidiary of Mogrify Ltd (Mogrify), a UK company … Continue reading →

April 1, 19

Metrion Biosciences Closes Funding Round

Includes investment from o2h Ventures Therapeutics Fund Funding to support expansion of ion channel screening capabilities and continued research into potential drugs for auto-immune diseases Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research … Continue reading →

April 1, 19

Mologic expands US and UK operations

Strengthens team as part of continued international expansion Bolsters US presence with the opening of subsidiary in Boston, MA Doubles device manufacturing capacity in UK Bedfordshire, UK, 1 April 2019: Mologic Ltd, a leading developer of lateral flow and rapid … Continue reading →